Polycationic peptide coatings and methods of coating implantable medical devices

• US 7,875,286 B2
• Filed: 08/26/2005
• Issued: 01/25/2011
• Est. Priority Date: 06/21/2002
• Status: Expired due to Fees

• Current Assignee: Advanced Cardiovascular Systems Incorporated
• Original Assignee: Advanced Cardiovascular Systems Incorporated
• Inventors: Michal, Eugene T., Roorda, Wouter E., Pacetti, Stephen D., Hossainy, Syed F. A., Ding, Ni
• Primary Examiner(s): Azpuru; Carlos A
• Application Number:
  US11/213,290
• Publication Number:
  US 20060018944A1
• Time in Patent Office: 1,978 Days
• Field of Search: None
• US Class Current: 424/426
• CPC Class Codes: A61K 31/727 Heparin; Heparan
• CPC Class Codes: A61K 31/728 Hyaluronic acid
• CPC Class Codes: A61K 31/737 Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate A61K31/727 takes precedence
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: C08L 89/00 Compositions of proteins; Compositions of derivatives thereof foodstuff preparations A23J3/00

Abstract

Coatings for medical devices which include polycationic peptides such as L-arginine and methods for fabricating the coatings are disclosed.

Claims

1. A coating for an implantable medical device comprising a polycationic polyelectrolyte and a polyanionic polyelectrolyte.

2. The coating of claim 1, wherein the medical device comprises a stent.

3. The coating of claim 1, wherein the polycationic polyelectrolyte comprises a component selected from the group consisting of poly(L-arginine), poly(D-arginine), poly(D,L-arginine), poly(L-lysine), poly(D-lysine), poly(δ

-guanidino-α

-aminobutyric acid), a racemic mixture of poly(L-arginine) and poly(D-arginine), chitosan, and a combination thereof.

4. The coating of claim 1, wherein the polyanionic polyelectrolyte comprises a component selected from the group consisting of heparin, a derivative of heparin, an oligonucleotide, RNA, chondroitin sulfate, dextran sulfate, hyaluronic acid, a hyaluronate, carboxymethyl cellulose, poly(acrylic acid), poly(methacrylic acid), poly(ethyl acrylic acid), poly(propyl acrylic acid), poly(ethylene-co-acrylic acid), poly(ethylene-co-methacrylic acid), and a combination thereof.

5. The coating of claim 1, wherein the polycationic polyelectrolyte comprises hepta-arginine.

6. The coating of claim 1, wherein the polyanionic polyelectrolyte comprises heparin.

7. The coating of claim 1, wherein the polycationic polyelectrolyte comprises hepta-arginine and the polyanionic polyelectrolyte comprises heparin.

17. A method of delivering an agent to a mammalian tissue, the method comprising contacting the mammalian tissue with the coating of claim 1 under in vivo conditions wherein contacting the mammalian tissue with the coating of claim 1 comprises contacting the mammalian tissue with an implantable medical device comprising the coating of claim 1.

18. The method of claim 17, wherein the tissue comprises a vascular tissue.

19. The method of claim 17, wherein the agent comprises hepta-arginine.

20. The method of claim 17, wherein the polyanionic polyelectrolyte comprises heparin.

21. The method of claim 17, wherein the polycationic polyelectrolyte comprises hepta-arginine and the polyanionic polyelectrolyte comprises heparin.

22. A method of preventing or treating a disease in a patient comprising implanting an implantable medical device comprising the coating of claim 1 in a vascular lumen of the patient.

23. The method of claim 22, wherein the polycationic polyelectrolyte comprises hepta-arginine.

24. The method of claim 22, wherein the polyanionic polyelectrolyte comprises heparin.

25. The method of claim 22, wherein the polycationic polyelectrolyte comprises hepta-arginine and the polyanionic polyelectrolyte comprises heparin.

26. The method of claim 22, wherein the disease comprises a vascular disease comprising restenosis, vulnerable plaque, or a combination thereof.

27. The method of claim 22, wherein the implantable medical device is a stent.

8. A method for coating an implantable medical device, wherein the method comprises applying alternating layers of a polycationic polyelectrolyte and a polyanionic polyelectrolyte onto the device.

9. The method of claim 8, wherein the medical device comprises a stent.

10. The method of claim 8, wherein the polycationic polyelectrolyte comprises a component selected from the group consisting of poly(L-arginine), poly(D-arginine), poly(D,L-arginine), poly(L-lysine), poly(D-lysine), poly(δ

-guanidino-α

-aminobutyric acid), a racemic mixture of poly(L-arginine) and poly(D-arginine), chitosan, and a combination thereof.

11. The method of claim 8, wherein the polycationic polyelectrolyte is in a free base form or an ionic form.

12. The method of claim 8, wherein the polyanionic polyelectrolyte comprises a component selected from the group consisting of heparin, a derivative of heparin, an oligonucleotide, RNA, chondroitin sulfate, dextran sulfate, hyaluronic acid, a hyaluronate, carboxymethyl cellulose, poly(acrylic acid), poly(methacrylic acid), poly(ethyl acrylic acid), poly(propyl acrylic acid), poly(ethylene-co-acrylic acid), poly(ethylene-co-methacrylic acid), and a combination thereof.

13. The method of claim 8, wherein the polyanionic polyelectrolyte is in an acid form or an ionic form.

14. The method of claim 8, wherein the polycationic polyelectrolyte comprises hepta-arginine.

15. The method of claim 8, wherein the polyanionic polyelectrolyte comprises heparin.

16. The method of claim 8, wherein the polycationic polyelectrolyte comprises hepta-arginine and the polyanionic polyelectrolyte comprises heparin.